Copastin

Quick links to important sections

Copastin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Copastin

Quick Facts

Property Description
Active ingredient Cloperastine (Hydrochloride or Fendizoate salts)
Form Oral Syrup (Suspension), Oral Tablets
Pharmacological class Antitussive agent (Non-opioid)
General purpose Suppresses the cough reflex to relieve dry, irritating coughs
Origin Synthetic compound (Diphenylmethane class)

What Pharmacological Class Does Copastin Belong To?

Copastin is a synthetic drug categorized as a centrally-acting, non-opioid antitussive agent, designed to provide relief by suppressing cough. Its active ingredient is Cloperastine, which is chemically classified within the Diphenylmethane group of compounds. The World Health Organization (WHO) designates Cloperastine with the ATC code R05DB21, placing it among other cough suppressants. This classification confirms that the medicine functions by regulating the central cough center, distinguishing it from opioid-derived cough suppressants by acting without the potential for physical dependence.

Composition and Forms: Cloperastine Salts (Hcl and Fendizoate)

The active ingredient Cloperastine is formulated as a single active ingredient product, most commonly using salt forms such as Cloperastine Hydrochloride (Hcl) or Cloperastine Fendizoate. It is available for oral administration in two high-level forms: tablets and syrup (an aqueous suspension base). The use of different salt forms primarily relates to optimizing the medicine's physical properties for formulation; for example, the Fendizoate salt is often utilized in suspension preparations which are particularly suited for pediatric groups and ease of swallowing.

The General Purpose of This Cough Suppressant

The general purpose of Cloperastine is to effectively calm the cough reflex to relieve persistent, dry, irritating coughs. It achieves this primarily through its direct central action, reducing the over-sensitivity of the signals that initiate coughing spasms. Cloperastine is used as an antitussive agent for cough symptom relief in cases of non-productive cough. Furthermore, Cloperastine possesses a dual mechanism, which includes mild antihistaminic properties that contribute to easing minor airway irritation that can provoke coughing.

What side effects are possible with Copastin?

Possible Side Effects and Safety Information

The safety profile of Copastin is established through regulatory documentation, which defines documented adverse reactions, their classifications, and specific limitations on use.

Documented Adverse Reactions

The following are adverse effects officially listed in regulatory summaries, grouped by the affected body system. The frequency of occurrence for many effects is often listed as not known (cannot be estimated from available data).

System-Organ Class Common Adverse Reactions
Nervous System Disorders Drowsiness (Somnolence), Sedation, Dizziness
Gastrointestinal Disorders Dry mouth, Gastric disturbances, Nausea, Vomiting
Eye Disorders Accommodation disturbances
Cardiac Disorders Palpitations (increased heart rate)
Immune System/General Allergic reaction (e.g., rash, itching)

Safety Considerations for Specific Populations

Official labeling includes specific constraints regarding certain patient groups:

  • Children: The medicine is contraindicated for use in children under 2 years of age.
  • Pregnancy and Lactation: Use is not recommended as safety during human pregnancy and while breastfeeding is not established.
  • Elderly Patients: The medication should be administered with caution.

Regulatory Constraints and Safety Limitations

Key safety limitations defined in regulatory documents include:

  • Central Nervous System (CNS) Effects: Due to the potential for drowsiness and sedation, the medicine carries a warning regarding the impairment of the ability to drive or use machinery.
  • Drug Interactions: Use is contraindicated in patients receiving concomitant treatment with MAO inhibitors. The drug can enhance the sedative effect of other CNS depressors.
  • Pre-existing Conditions: Caution is advised when administering to patients with underlying conditions such as narrow-angle glaucoma, prostatic hypertrophy, or hypertension.

Overdose and Emergency Response

The official regulatory profile for Cloperastine (Copastin) overdose focuses on severe central nervous system (CNS) and cardiovascular effects following the ingestion of quantities much higher than therapeutic doses. Documented clinical manifestations of overdose include profound CNS changes such as drowsiness, sedation, hallucinations, and general anticholinergic symptoms. More severe neurological presentations noted in regulatory documentation are convulsions, toxic psychosis, and ataxia (lack of motor coordination).

Overdose may lead to life-threatening systemic outcomes, including apnea (cessation of breathing), arrhythmia (abnormal heart rhythm), and cardiovascular collapse. Due to these potential severe outcomes, the regulatory requirement is to seek immediate medical attention.

Management of overdose is strictly symptomatic and maintenance treatment, as no specific antidote is known. Officially described procedures for intoxication include gastric lavage with saline serum or the induction of vomiting. Furthermore, regulatory notes indicate that children and the elderly are more susceptible to adverse neurological effects, specifically paradoxical excitation, in overdose situations. The presence of life-threatening symptoms necessitates the administration of basic and advanced life support.

Therapeutic Uses of Copastin

What Copastin Treats: Main Uses and Benefits

Addressing Dry, Irritating, and Non-Productive Cough

The drug's core therapeutic purpose is categorized within the domain of cough suppressants used for symptomatic support. This domain generally supports the easing of dry, non-productive coughs—the type of symptoms related to physical discomfort that interfere with daily functioning. It is commonly used to help with symptom clusters associated with acute conditions, such as the common cold and acute bronchitis, and is relevant when symptoms create noticeable physiological strain, especially during periods of rest.

Symptomatic Support in Acute and Chronic Contexts

Copastin is applied across domains where additional symptomatic support is needed, particularly in conditions involving episodic or fluctuating manifestations like patterns seen in chronic respiratory contexts. The medication may assist with easing the overall symptom burden and contributes to improved comfort. It is often used to help with symptom clusters that may become intense or disruptive, assisting with managing day-to-day comfort and supporting patients during episodes of heightened discomfort.


Quick Fact: Focus on Dry, Irritating Cough Symptoms The therapeutic domain is focused on suppression for non-productive coughs—those without mucus—across both acute episodes and chronic symptomatic patterns.

Regulatory References

  1. European Directorate for the Quality of Medicines (EDQM)

Eligibility and Restrictions for Use

Copastin (cloperastine) is primarily used for the symptomatic relief of non-productive, dry cough in adults. Its use is generally considered safe for most healthy adults when taken as directed for a short duration.


Contraindications

Copastin should not be used by certain individuals due to the risk of adverse effects or complications. Absolute contraindications include:

  • Known hypersensitivity or allergy to cloperastine or any of the inactive ingredients in the formulation.
  • Children: Use in children, particularly those under the age of six, is generally not recommended or established.

Caution and Consultation

Consultation with a healthcare provider is essential before using Copastin if you have pre-existing medical conditions or belong to specific patient populations. Use with caution is advised for individuals with:

  • Pregnancy and Breastfeeding: Safety has not been definitively established; use only if the potential benefit outweighs the risk.
  • Glaucoma or conditions that may predispose to urinary retention (such as prostatic hypertrophy), due to the drug's mild anticholinergic properties.
  • Severe cardiovascular disease.
  • Liver or kidney impairment.

Healthcare providers must also be informed of all other medications being taken to check for potential drug-drug interactions, particularly with central nervous system depressants like alcohol or certain antihistamines, which may enhance drowsiness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cloperastine (Copastin) is defined by pharmacodynamic interactions, which involve the reciprocal enhancement of effects with certain classes of medicines and substances.

Interaction Scope and Restrictions

Medicinal product categories with documented interactions include Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, Anticholinergic Drugs, Alcohol, and Expectorants/Mucolytic Drugs.

The primary interaction-related restriction is a formal prohibition against the co-administration of Cloperastine with Monoamine Oxidase Inhibitors (MAOIs). This constitutes a regulatory contraindication due to the potential for reciprocally increased effects.

Pharmacodynamic Effects and Regulatory Caution

The mechanistic basis of the interactions is primarily pharmacodynamic. Co-administration with CNS depressants (such as certain anxiolytics, sedatives, hypnotics, narcotics, and antipsychotic drugs) or alcohol can lead to the enhancement of the sedative effect of Cloperastine.

Similarly, combining Cloperastine with other anticholinergic drugs can result in a reciprocal increase in their effects.

A specific, label-documented caution applies to the simultaneous use of Cloperastine with expectorants or mucolytic drugs. The antitussive action (inhibition of the cough reflex) in this context may present a safety risk described as potential pulmonary obstruction if the volume or fluidity of bronchial secretions increases.

No official regulatory labels document specific pharmacokinetic interactions mediated by CYP enzymes, nor are there listed timing requirements or population-specific interaction adjustments.

Mechanism of Action

Copastin exerts a selective effect by binding to the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). RANKL is a transmembrane or soluble protein found on the surface of osteoblasts, osteocytes, and T-lymphocytes. The targeted binding of Copastin to RANKL inhibits the interaction between RANKL and its receptor, RANK, located on the surface of pre-osteoclast cells. This antagonism blocks the crucial signaling cascade required for osteoclastogenesis (the differentiation, fusion, and activation of osteoclasts). By inhibiting osteoclast activity, Copastin directly modulates the bone remodeling process, leading to a reduction in bone resorption activity. Furthermore, the mechanism modulates the Wnt signaling pathway, which is associated with promoting osteoblast differentiation. This dual action contributes to a sustained shift in the bone remodeling equilibrium toward bone formation.

Dosage and Administration Information

How to Use Copastin: Official Administration Guidelines

Copastin, containing Cloperastine, is administered exclusively via the oral route, available as both tablets and an oral suspension (syrup). Usage must strictly adhere to established dosing patterns.


Administration Scope

Instruction Official Rule
Route of administration The medicine is administered via the oral route (syrup or tablets).
Standard Adult Dose The typical daily dose range is 20 to 40 mg (Hydrochloride equivalent), administered in divided doses. The standard syrup dose is 10 mL per administration.
Frequency and timing The syrup dose is typically administered three times a day (t.i.d.), preferably timed for the morning, noon, and night.
Timing in relation to meals It is advisable to administer the oral syrup product before meals.
Preparation requirements The bottle of oral suspension (syrup) must be shaken thoroughly before the medicine is administered.

Age-Group Administration Rules

Dosing is strictly adjusted for pediatric patients based on age. The medicine is not recommended for use in children under 2 years of age. The dosage for older children is as follows:

  • Children 6 to 12 years: 5 mL administered three times a day.
  • Children 2 to 6 years: 2.5 mL administered three times a day.

Use Duration Protocol

The medicine is intended for short-term use for symptomatic relief. Any usage extended beyond a short course should be conducted only under strict medical supervision.

Recent Clinical Evidence

Research evidence / Overview of Studies for Copastin

This section summarizes the structure of the official clinical research and scientific literature that informs the study of Copastin, focusing on the types of studies conducted, the populations evaluated, and the areas where research remains limited. It is a non-advisory overview of the evidence base.


Evidence from Randomized Controlled Trials (RCTs)

Research related to the agent, particularly within the study of cough symptoms, relies on Randomized Controlled Trials (RCTs). These short-term clinical trials were used in research exploring how symptoms change over time when compared against a placebo or other comparative agents. The findings from these trials have been consolidated into Systematic Reviews and Meta-Analyses, which contribute to the study framework considered by health regulators.

Studies in Acute Respiratory Contexts

This research scenario explores short-term symptom changes, primarily in the context of cough associated with acute conditions like the common cold or acute bronchitis. Studies monitored how symptoms were recorded in the observed populations, with outcomes including the Frequency and Intensity of Cough and the degree of sleep interference. The structured methodology of these randomized trials contributes to the assignment of a High evidence level to this research area by scientific bodies.

Evidence Regarding Persistent Cough Symptoms

Research for persistent cough symptoms—those lasting beyond the acute phase—is less uniform. This evidence base consists of Smaller-Scale Comparative Studies and observational settings, primarily examining adult populations. Studies reported patterns related to measured symptom outcomes over intermediate observation periods, but the findings were mixed across the different study designs. The evidence base for this symptomatic context is broadly considered Moderate.

Key Limitations and Research Gaps

The research landscape is structurally limited, as the most robust evidence primarily relates to short-term changes associated with acute conditions. Information regarding symptomatic outcomes during extended or continuous use remains an area where research is still emerging. Furthermore, the findings describe group patterns, and results apply only to the populations studied. Data for certain special groups, such as those with certain pre-existing chronic conditions, often remain insufficient for comprehensive characterization.

Key Studies & References

  1. Pharmacological and clinical overview of cloperastine in treatment of cough
  2. committee of experts on the classification of medicines as regards their supply (cd-p-ph/pho - Includes EU regulatory context on safety/supply)
  3. Comparative Analysis of Classic and Novel Antitussives on Cough Suppression in Guinea Pigs (Preclinical context for antitussive effect)

Frequently Asked Questions (FAQ)

Common questions about Copastin (FAQ)

Q: How long does it typically take to start feeling the effects of Copastin?

Information from pharmacokinetic studies, which describe how a drug moves through the body, indicates that the active ingredient may reach its highest concentration in the blood within approximately 40 to 60 minutes after administration. This data is descriptive of the drug's absorption profile.

Q: Does Copastin cause drowsiness or make it unsafe to drive?

Official product labeling notes the need for caution regarding activities that require full concentration, such as driving or operating heavy machinery, due to the documented risk of side effects like dizziness and drowsiness.

Q: Are there any known issues with drinking alcohol while taking Copastin?

The regulatory label indicates that consuming alcohol while using the product can lead to an enhancement of the sedative effects. This information is provided to describe the potential for increased drowsiness or sedation if alcohol is consumed.

Q: What is the meaning of the specific safety warning (Black Box) sometimes associated with this class of drug?

A Black Box Warning is the strongest safety notification the FDA uses to highlight very serious risks associated with a medicine. While this type of warning is used for serious risks, official documentation for the active ingredient in Copastin does not specifically list a Black Box Warning.

Q: How does Copastin affect the immune system?

The drug's mechanism of action involves targeting a protein called Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). While this pathway is primarily known for its role in bone remodeling, official descriptions also mention that RANKL is found on cells of the immune system, such as T-lymphocytes.

Q: How is Copastin eliminated from the body?

Pharmacokinetic data describes that the active medicine is metabolized, or broken down, by the body into compounds that are no longer active. These resulting inactive compounds are then primarily excreted from the body through the urine.

Q: What is the maximum time a person is generally expected to be on Copastin?

Copastin is officially designated for short-term symptomatic relief. Clinical studies supporting the product's use often evaluate treatment periods lasting up to approximately 7 days, consistent with its short-term designation.

Q: What are some of the less common but important side effects to be aware of when using Copastin?

The comprehensive list of documented adverse effects in official drug information includes events listed as uncommon or rare. These can include mild stomach issues, dizziness, vertigo (a feeling of spinning), and certain allergic skin reactions. This information is described in detail in the full prescribing information.

Q: Does taking Copastin affect my ability to get pregnant or affect fertility in general?

Official documents, based on studies conducted in animals, state that no direct or indirect harmful effects were found with respect to fertility or reproductive function.

Q: What should I do if I think I have accidentally taken too much Copastin?

The regulatory label addresses taking more than the prescribed amount, noting that the recognized symptoms primarily include increased drowsiness. In such scenarios, official sources state that management is generally supportive, aiming to address the symptoms.

Q: How does Copastin relate to the condition it treats—does it cure it or manage symptoms?

Official regulatory indications consistently describe the drug's purpose as providing symptomatic relief for the condition it addresses. This designation means the drug is intended to manage the patient's symptoms rather than provide a cure for the underlying issue.

Q: What is the consensus on the long-term use of Copastin?

The most robust research evidence for Copastin supports its effects during short-term use. Official sources indicate that information regarding outcomes and safety during extended or continuous use remains an area where studies are still emerging.

Q: How quickly do the side effects of Copastin usually go away after stopping the medication?

The duration of action for a single dose is described as short (approximately 3 to 4 hours). Therefore, temporary side effects are generally understood to have a relatively rapid offset profile once the medicine is stopped.

Q: Does Copastin have any specific storage instructions beyond 'room temperature'?

Official storage guidelines often include requirements to protect the medicine from direct sunlight, heat, and water. These documents typically specify a storage temperature not exceeding 30°C (86°F).

Q: Can Copastin be taken at any time of day, or is a specific schedule better?

Official dosage instructions state that the medicine is typically administered in divided doses three times a day (t.i.d.). The timing is often preferred for morning, noon, and night to support the intended schedule.

How should Copastin be stored and disposed of?

How to Store and Dispose of Copastin?

This section outlines the official, label-based storage and disposal requirements for Cloperastine (Copastin).

Required Storage Conditions

Condition Regulatory Requirement
Temperature Store at room temperature in a cool place, typically between 10 C and 25 C.
Protection Must be stored in a dark place, protected from direct sunlight and moisture.
Container Keep the product in its original packaging and ensure the container is tightly closed.
Child Safety Store the medication out of the sight and reach of children and pets.

Stability and Disposal

For liquid forms, the product may need to be discarded six months after the bottle is first opened. Unused or expired medication must be disposed of in accordance with local, regional, and national regulations. Do not flush the product down the toilet or pour it into a drain unless specifically instructed to do so by a healthcare authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Copastin found in:

A-Z Index: